一个基于支柱的纳米平台[5]arene纳米用于联合药物输送和增强抗瘤活性
Jianfeng Jiang1, Zhilian Su1, Qin He1
1Guangxi Colleges and Universities Key Laboratory of Applied Chemistry, Technology and Resource Development, School of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China.
Chemistry (Weinheim an der Bergstrasse, Germany)
|January 23, 2024
概括
这项研究引入了一种用于癌症治疗的新型双响应纳米药物输送系统. 该平台结合了化疗和饥饿治疗,以增强瘤抑制和生物相容性.
科学领域:
- 纳米技术纳米技术
- 在瘤学瘤学.
- 生物医学工程 生物医学工程
背景情况:
- 癌症单一疗法受到瘤异质性和药物副作用的限制.
- 开发先进的纳米药物输送系统对于有效的癌症治疗至关重要.
研究的目的:
- 开发一种新的pH和光双响应纳米药物输送平台,用于联合癌症治疗.
- 评估这个新纳米平台的有效性和生物相容性.
主要方法:
- 硫酸盐修饰的黄金纳米颗粒的制造,装有多克索鲁比 (DOX) 和葡萄糖氧化酶 (GOx).
- 封装使用支柱[5]arene作为控制药物释放的纳米.
- 利用pH响应用于瘤微环境向和光响应用于增强药物释放.
- 在体外和体内对治疗疗效和生物相容性的评估.
主要成果:
- 该纳米平台在弱酸性瘤环境中展示了增加的药物载荷能力和持续释放.
- 该系统有效地执行了联合化疗 (DOX) 和饥饿疗法 (GOx).
- 黄金纳米粒子促进光热转化,增强光照照射下药物释放.
- 在体外和体外的研究证实了与单一治疗相比,良好的生物相容性和优越的治疗疗效.
结论:
- 开发的纳米药物输送平台为癌症治疗提供了一个有前途的联合化疗/饥饿治疗策略.
- 这种双响应系统表现出显著的瘤抑制能力.
- 这项研究为先进的癌症治疗开发提供了新的途径.
相关概念视频
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...